본문 바로가기
KERD
논문KCI 등재

The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability

Chen Ying|Zhang Ping|Li Huan|Zhang Nan|Shen Yan|Lou Shifeng|Deng Jianchuan
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2022.12|Experimental and Molecular Medicine|제54권 |pp. 1-12|DOI 10.1038/s12276-022-00735-x

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

N6-methyladenosine (m6A) is the most abundant posttranscriptional modification of mRNA in eukaryotes. Recent evidence suggests that dysregulated m6A-associated proteins and m6A modifications play a pivotal role in the initiation and progression of diseases such as cancer. Here, we identified that IGF2BP3 is specifically overexpressed in acute myeloid leukemia (AML), a subtype of leukemia associated with poor prognosis and high genetic risk. IGF2BP3 is required for maintaining AML cell survival in an m6A-dependent manner, and knockdown of IGF2BP3 dramatically suppresses the apoptosis, reduces the proliferation, and impairs the leukemic capacity of AML cells in vitro and in vivo. Mechanistically, IGF2BP3 interacts with RCC2 mRNA and stabilizes the expression of m6A-modified RNA. Thus, we provided compelling evidence demonstrating that the m6A reader IGF2BP3 contributes to tumorigenesis and poor prognosis in AML and can serve as a target for the development of cancer therapeutics.

Abstract

N6-methyladenosine (m6A) is the most abundant posttranscriptional modification of mRNA in eukaryotes. Recent evidence suggests that dysregulated m6A-associated proteins and m6A modifications play a pivotal role in the initiation and progression of diseases such as cancer. Here, we identified that IGF2BP3 is specifically overexpressed in acute myeloid leukemia (AML), a subtype of leukemia associated with poor prognosis and high genetic risk. IGF2BP3 is required for maintaining AML cell survival in an m6A-dependent manner, and knockdown of IGF2BP3 dramatically suppresses the apoptosis, reduces the proliferation, and impairs the leukemic capacity of AML cells in vitro and in vivo. Mechanistically, IGF2BP3 interacts with RCC2 mRNA and stabilizes the expression of m6A-modified RNA. Thus, we provided compelling evidence demonstrating that the m6A reader IGF2BP3 contributes to tumorigenesis and poor prognosis in AML and can serve as a target for the development of cancer therapeutics.

참고문헌 (39)

  1. Jörg Westermann, "Precision medicine in myeloid malignancies", Seminars in Cancer Biology, 84, pp.153~169 (2021), Elsevier BV[DOI]
  2. Wouters, B. J., "Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia", Blood, 127, pp.42~52 (2016)
  3. Zhang, N., "Comprehensive analysis the potential biomarkers for the high-risk of childhood acute myeloid leukemia based on a competing endogenous RNA network", Blood Cells Mol. Dis, 79, pp.102352~ (2019)
  4. Zhang, N., "Clusterization in acute myeloid leukemia based on prognostic alternative splicing signature to reveal the clinical characteristics in the bone marrow microenvironment", Cell Biosci, 10, pp.118~ (2020)
  5. Nan Zhang, "Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia", Therapeutic Advances in Medical Oncology, 12, pp.175883592092763~ (2020), SAGE Publications[DOI]
  6. Zhang, N., "A six-gene-based prognostic model predicts complete remission and overall survival in childhood acute myeloid leukemia", Onco. Targets Ther, 12, pp.6591~6604 (2019)
  7. Huang, H., "m6A modification in coding and non-coding RNAs : roles and therapeutic implications in cancer", Cancer Cell, 37, pp.270~288 (2020)
  8. Deng, X., "RNA N6-methyladenosine modification in cancers : current status and perspectives", Cell Res, 28, pp.507~517 (2018)
  9. Zaccara, S., "Reading, writing and erasing mRNA methylation", Nat. Rev. Mol. Cell Biol, 20, pp.608~624 (2019)
  10. Huang, W., "N6-methyladenosine methyltransferases : functions, regulation, and clinical potential", J. Hematol. Oncol, 14, pp.117~ (2021)
  11. Barbieri, I., "Promoter-bound METTL3 maintains myeloid leukaemia by m6Adependent translation control", Nature, 552, pp.126~131 (2017)
  12. Vu, L. P., "The N6-methyladenosine(m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells", Nat. Med, 23, pp.1369~1376 (2017)
  13. Li, Z., "FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase", Cancer Cell, 31, pp.127~141 (2017)
  14. Huang, Y., "Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia", Cancer Cell, 35, pp.677~691.e10 (2019)
  15. Shen, C., "RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia", Cell Stem Cell, 27, pp.64~80.e9 (2020)
  16. Meyer, K. D., "Rethinking m6A readers, writers, and erasers", Annu. Rev. Cell Dev. Biol, 33, pp.319~342 (2017)
  17. Jung, S. M., "Smad6 inhibits non-canonical TGF-β1 signalling by recruiting the deubiquitinase A20 to TRAF6", Nat. Commun, 4, pp.2562~ (2013)
  18. Bertacchini, J., "Feedbacks and adaptive capabilities of the PI3K", Akt, Leukemia, pp.2014, 28[DOI]
  19. Ramakrishnan, R., "CXCR4 signaling has a CXCL12-independent essential role in murine MLL-AF9-driven acute myeloid leukemia", Cell Rep, 31, pp.107684~ (2020)
  20. Huang, H., "Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation", Nat. Cell Biol, 20, pp.18~ (2018)
  21. Zhang, S., "m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program", Cancer Cell, 31, pp.591~606.e6 (2017)
  22. Palanichamy, J. K., "RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation", J. Clin. Invest, 126, pp.18~ (2016)
  23. Zhou, Y., "SRAMP : prediction of mammalian N6-methyladenosine(m6A)sites based on sequence-derived features", Nucleic Acids Res, 44, pp.e91~ (2016)
  24. Fu, Y., "Gene expression regulation mediated through reversible m6A RNA methylation", Nat. Rev. Genet, 15, pp.293~306 (2014)
  25. Qing, Y., "R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO", m6A, LDHB axis, pp.Mol. Cell, 2021[DOI]
  26. Wang, J., "Leukemogenic chromatin alterations promote AML leukemia stem cells via a KDM4C-ALKBH5-AXL signaling axis", Cell Stem Cell, 27, pp.81~97.e8 (2020)
  27. Roundtree, I. A., "Dynamic RNA modifications in gene expression regulation", Cell, 169, pp.1187~1200 (2017)
  28. Burdelski, C., "IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features : a tissue microarray study on 8, 877human cancers and normal tissues", Oncol. Rep, 39, pp.3~12 (2018)
  29. Mancarella, C., "IGF2BP3 from physiology to cancer : novel discoveries, unsolved issues, and future perspectives", Front. Cell Dev. Biol, 7, pp.363~ (2019)
  30. Elcheva, I. A., "RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1", Leukemia, 34, pp.1354~1363 (2020)
  31. Su, R., "R-2HG exhibits anti-tumor activity by targeting FTO", m6A, CEBPA signaling, pp.Cell, 2018[DOI]
  32. Paris, J., "Targeting the RNA m6A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia", Cell Stem Cell, 25, pp.137~148.e6 (2019)
  33. Mapperley, C., "The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function", J. Exp. Med, 218, pp.e20200829~ (2021)
  34. Wang, H., "Loss of YTHDF2-mediated m6A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration", Cell Res, 28, pp.1035~1038 (2018)
  35. Pang, B., "Overexpression of RCC2 enhances cell motility and promotes tumor metastasis in lung adenocarcinoma by inducing epithelial-mesenchymal transition", Clin. Cancer Res, 23, pp.5598~5610 (2017)
  36. Chen, Q., "RCC2 contributes to tumor invasion and chemoresistance to cisplatin in hepatocellular carcinoma", Hum. Cell, 33, pp.709~720 (2020)
  37. Wu, N., "RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation", BMC Cancer, 18, pp.67~ (2018)
  38. Wu, Q., "BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression", Oncogene, 41, pp.374~360 (2022)
  39. Su, R., "Targeting FTO suppresses cancer stem cell maintenance and immune evasion", Cancer Cell, 38, pp.79~96.e11 (2020)

관련 논문AI추천

Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer typesAn Joon-Yong, Cho Sung-Yup, Hwa Chanwoong, Jang Dongjun, Jang Giyong, Jung Hae Rim, Kim Jiwon, Kwon Obin, Lee Sang Eun, Lee Soojin, Oh Jaeik, Oh Yumi, Shin Seungjae생화학분자생물학회 · Experimental and Molecular Medicine2022 · 제54권 Biological roles of the RNA m6A modification and its implications in cancerHong Juyeong, Lee Ji Hoon, Xu Kexin생화학분자생물학회 · Experimental and Molecular Medicine2022 · 제54권 Deciphering the molecular mechanisms of epitranscriptome regulation in cancerJunho Choe, Seung Hun Han생화학분자생물학회 · BMB Reports2021 · 제54권 제2호The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: classification, mechanisms, and potential therapeutic implicationsCheng Long, Gao Lei, Liu Ziying, Lv Gaoyuan, Sun Bei, Tang Qiushi, Wang Gang생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Loss of YTHDC1 m6A reading function promotes invasiveness in urothelial carcinoma of the bladderErben Philipp, Koch Jonas, Lyko Frank, Michel Maurice Stephan, Neuberger Manuel, Nientiedt Malin, Rodríguez-Paredes Manuel, Schmidt Claudia, Xu Jinyun생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권 Comprehensive profiling of RNA modification-related genes identifies RNA m7G binding protein CBP20 as a therapeutic target for tumor growth inhibitionChoi Jae-Mun, Cho Sung-Yup, Cho Yoonsung, Jang Dongjun, Jung Hae Rim, Kim Dohee, Kim Jiwon, Lee Sang Eun, Lee Soojin, Oh Jaeik, Oh Yumi, Park Young Bin, Shin Seungjae, Yang Yoojin생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권

이 간행물의 다른 논문 (191건)

Particulate matter promotes cancer metastasis through increased HBEGF expression in macrophages이효진, Park Jun-Young, Lee Moo-Seung, Kim Dae-Soo, Son Mi-Young, Jeong Jinyoung, 박영준, Cho Young-Lai, Lee Seon-Jin, Park Seung-Ho, Yoon Sung-Jin, Choi Song, Jung Jaeeun, Park Young-Ho, Seo Jinho, Lee Jungwoon, Kim Jang-Seongpp. 1-12WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function권호근, 김현석, Yoon Hyun Ju, Kim Gi-Cheon, Oh Sejin, Kim Hakhyun, Kim Yong Keon, Lee Yunji, Kim Min Seo, Kwon Gino, Ok Yeon-Supp. 1-14Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagyFeng Ji, Wu Yong, Zhou Jing, Dai Hui-Qi, Zhu Guang-Zhi, Chen Pan-Hong, Wang Li-Ming, Lu Guang, Liao Xi-Wen, Lu Pei-Zhi, Su Wen-Jing, Hooi Shing Chuan, Ye Xin-Pin, Shen Han-Ming, Peng Tao, Lu Guo-Dongpp. 1-15Hypoxia-induced circRNF13 promotes the progression and glycolysis of pancreatic cancerZhao Qiuyan, Zhu Zhonglin, Xiao Wenqin, Zong Guanzhao, Wang Chuanyang, Jiang Weiliang, Li Kai, Shen Jie, Guo Xingya, Cui Jianhua, Guo Lihong, Wan Rongpp. 1-15The transcriptional profile of keloidal Schwann cellsDireder Martin, Wielscher Matthias, Weiss Tamara, Laggner Maria, Copic Dragan, Klas Katharina, Bormann Daniel, Vorstandlechner Vera, Tschachler Erwin, Jan Ankersmit Hendrik, Mildner Michaelpp. 1-15
원문 보기